All Stories

  1. Pharmacogenetics of Anticoagulation and Clinical Events in Warfarin-Treated Patients: A Register-Based Cohort Study with Biobank Data and National Health Registries in Finland

    Article • Clinical Epidemiology, March 2021, Taylor & Francis

    Dr Mikko Niemi

  2. Vegan diet in young children remodels metabolism and challenges the statuses of essential nutrients

    Article • EMBO Molecular Medicine, January 2021, EMBO

    Dr Mikko Niemi

  3. UGT1A3 and Sex Are Major Determinants of Telmisartan Pharmacokinetics—A Comprehensive Pharmacogenomic Study

    Article • Clinical Pharmacology & Therapeutics, July 2020, Wiley

    Dr Mikko Niemi

  4. Itraconazole Increases Ibrutinib Exposure 10‐Fold and Reduces Interindividual Variation—A Potentially Beneficial Drug‐Drug Interaction

    Article • Clinical and Translational Science, November 2019, Wiley

    Dr Mikko Niemi

  5. Enantiospecific Pharmacogenomics of Fluvastatin

    Article • Clinical Pharmacology & Therapeutics, May 2019, Wiley

    Dr Mikko Niemi

  6. Clopidogrel and Gemfibrozil Strongly Inhibit the CYP2C8-Dependent Formation of 3-Hydroxydesloratadine and Increase Desloratadine Exposure In Humans

    Article • Drug Metabolism and Disposition, January 2019, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mikko Niemi

  7. Clopidogrel Increases Dasabuvir Exposure With or Without Ritonavir, and Ritonavir Inhibits the Bioactivation of Clopidogrel

    Article • Clinical Pharmacology & Therapeutics, August 2018, Wiley

    Dr Mikko Niemi

  8. Ketamine and norketamine attenuate oxycodone tolerance markedly less than that of morphine: from behaviour to drug availability

    Article • British Journal of Anaesthesia, April 2018, Elsevier

    Dr Mikko Niemi

  9. Transporter-Mediated Alterations in Patients With NASH Increase Systemic and Hepatic Exposure to an OATP and MRP2 Substrate

    Article • Clinical Pharmacology & Therapeutics, February 2018, Wiley

    Dr Mikko Niemi

  10. Safety of Single-Dose Primaquine in G6PD-Deficient and G6PD-Normal Males in Mali Without Malaria: An Open-Label, Phase 1, Dose-Adjustment Trial

    Article • The Journal of Infectious Diseases, January 2018, Oxford University Press (OUP)

    Dr Mikko Niemi

  11. Safety of single low-dose primaquine in glucose-6-phosphate dehydrogenase deficient falciparum-infected African males: Two open-label, randomized, safety trials

    Article • PLoS ONE, January 2018, PLOS

    Dr Mikko Niemi

  12. Interactions of (2S,6S;2R,6R)-Hydroxynorketamine, a Secondary Metabolite of (R,S)-Ketamine, with Morphine

    Article • Basic & Clinical Pharmacology & Toxicology, December 2017, Wiley

    Dr Mikko Niemi

  13. Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans

    Article • Clinical Pharmacology & Therapeutics, December 2017, Wiley

    Anne Filppula, Dr Mikko Niemi

  14. Effects of Genetic Variants on Carboxylesterase 1 Gene Expression, and Clopidogrel Pharmacokinetics and Antiplatelet Effects

    Article • Basic & Clinical Pharmacology & Toxicology, November 2017, Wiley

    Dr Mikko Niemi

  15. Clopidogrel Carboxylic Acid Glucuronidation is Mediated Mainly by UGT2B7, UGT2B4, and UGT2B17: Implications for Pharmacogenetics and Drug-Drug Interactions

    Article • Drug Metabolism and Disposition, November 2017, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mikko Niemi

  16. Comprehensive Pharmacogenomic Study Reveals an Important Role of UGT1A3 in Montelukast Pharmacokinetics

    Article • Clinical Pharmacology & Therapeutics, November 2017, Wiley

    Dr Mikko Niemi

  17. Novel copy-number variations in pharmacogenes contribute to interindividual differences in drug pharmacokinetics

    Article • Genetics in Medicine, October 2017, Springer Science + Business Media

    Dr Mikko Niemi

  18. Analgesic Plasma Concentrations of Oxycodone After Surgery for Breast Cancer—Which Factors Matter?

    Article • Clinical Pharmacology & Therapeutics, August 2017, Wiley

    Dr Mikko Niemi

  19. Age, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children

    Article • Antimicrobial Agents and Chemotherapy, March 2017, ASM Journals

    Dr Mikko Niemi

  20. Do Diuretics have Antinociceptive Actions: Studies of Spironolactone, Eplerenone, Furosemide and Chlorothiazide, Individually and with Oxycodone and Morphine

    Article • Basic & Clinical Pharmacology & Toxicology, July 2016, Wiley

    Dr Mikko Niemi

  21. Primaquine to reduce transmission of Plasmodium falciparum malaria in Mali: a single-blind, dose-ranging, adaptive randomised phase 2 trial

    Article • The Lancet Infectious Diseases, June 2016, Elsevier

    Dr Mikko Niemi

  22. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions

    Article • Pharmacological Reviews, December 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mikko Niemi

  23. Clopidogrel Has No Clinically Meaningful Effect on the Pharmacokinetics of the Organic Anion Transporting Polypeptide 1B1 and Cytochrome P450 3A4 Substrate Simvastatin

    Article • Drug Metabolism and Disposition, September 2015, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mikko Niemi

  24. SLCO1B1 polymorphism markedly affects the pharmacokinetics of lovastatin acid

    Article • Pharmacogenetics and Genomics, August 2015, Wolters Kluwer Health

    Dr Mikko Niemi

  25. Drug-Related Inadvertent Deaths in a University Hospital - A Declining Trend

    Article • Basic & Clinical Pharmacology & Toxicology, July 2015, Wiley

    Dr Mikko Niemi

  26. Effect of carboxylesterase 1 c.428G > A single nucleotide variation on the pharmacokinetics of quinapril and enalapril

    Article • British Journal of Clinical Pharmacology, June 2015, Wiley

    Dr Mikko Niemi

  27. Effect of grapefruit juice on the bioactivation of prasugrel

    Article • British Journal of Clinical Pharmacology, June 2015, Wiley

    Dr Mikko Niemi

  28. Pregabalin enhances the antinociceptive effect of oxycodone and morphine in thermal models of nociception in the rat without any pharmacokinetic interactions

    Article • European Journal of Pain, May 2015, Wiley

    Dr Mikko Niemi

  29. Ketamine coadministration attenuates morphine tolerance and leads to increased brain concentrations of both drugs in the rat

    Article • British Journal of Pharmacology, May 2015, Wiley

    Dr Mikko Niemi

  30. Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans

    Article • Clinical Pharmacology & Therapeutics, May 2015, Wiley

    Dr Mikko Niemi

  31. Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops

    Article • Drug Metabolism and Disposition, September 2014, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mikko Niemi

  32. Glucuronidation Converts Clopidogrel to a Strong Time-Dependent Inhibitor of CYP2C8: A Phase II Metabolite as a Perpetrator of Drug–Drug Interactions

    Article • Clinical Pharmacology & Therapeutics, June 2014, Springer Science + Business Media

    Dr Mikko Niemi

  33. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update

    Article • Clinical Pharmacology & Therapeutics, June 2014, Springer Science + Business Media

    Dr Mikko Niemi

  34. Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: Influence on cure rates and risk of second cancer

    Article • Pediatric Blood & Cancer, January 2014, Wiley

    Dr Mikko Niemi

  35. PharmGKB summary

    Article • Pharmacogenetics and Genomics, December 2013, Wolters Kluwer Health

    Dr Mikko Niemi

  36. Grapefruit Juice Inhibits the Metabolic Activation of Clopidogrel

    Article • Clinical Pharmacology & Therapeutics, September 2013, Springer Science + Business Media

    Dr Mikko Niemi

  37. The mineralocorticoid receptor antagonist spironolactone enhances morphine antinociception

    Article • European Journal of Pain, July 2013, Wiley

    Dr Mikko Niemi

  38. International Transporter Consortium Commentary on Clinically Important Transporter Polymorphisms

    Article • Clinical Pharmacology & Therapeutics, July 2013, Springer Science + Business Media

    Dr Mikko Niemi

  39. Grapefruit juice markedly increases the plasma concentrations and antiplatelet effects of ticagrelor in healthy subjects

    Article • British Journal of Clinical Pharmacology, May 2013, Wiley

    Dr Mikko Niemi

  40. Gemfibrozil Impairs Imatinib Absorption and Inhibits the CYP2C8-Mediated Formation of Its Main Metabolite

    Article • Clinical Pharmacology & Therapeutics, May 2013, Springer Science + Business Media

    Dr Mikko Niemi

  41. Using Bayesian-PBPK modeling for assessment of inter-individual variability and subgroup stratification

    Article • In Silico Pharmacology, April 2013, Springer Science + Business Media

    Dr Mikko Niemi

  42. SLCO2B1 c.935G>A single nucleotide polymorphism has no effect on the pharmacokinetics of montelukast and aliskiren

    Article • Pharmacogenetics and Genomics, January 2013, Wolters Kluwer Health

    Dr Mikko Niemi

  43. A Mechanistic, Model-Based Approach to Safety Assessment in Clinical Development

    Article • CPT Pharmacometrics & Systems Pharmacology, November 2012, Wiley

    Dr Mikko Niemi

  44. Drug interactions with oral antidiabetic agents: pharmacokinetic mechanisms and clinical implications

    Article • Trends in Pharmacological Sciences, June 2012, Elsevier

    Dr Mikko Niemi

  45. The Clinical Pharmacogenomics Implementation Consortium: CPIC Guideline for SLCO1B1 and Simvastatin-Induced Myopathy

    Article • Clinical Pharmacology & Therapeutics, May 2012, Springer Science + Business Media

    Dr Mikko Niemi

  46. Carboxylesterase 1 Polymorphism Impairs Oseltamivir Bioactivation in Humans

    Article • Clinical Pharmacology & Therapeutics, May 2012, Springer Science + Business Media

    Dr Mikko Niemi

  47. PPARA: A Novel Genetic Determinant of CYP3A4 In Vitro and In Vivo

    Article • Clinical Pharmacology & Therapeutics, April 2012, Springer Science + Business Media

    Dr Mikko Niemi

  48. Gemfibrozil Is a Strong Inactivator of CYP2C8 in Very Small Multiple Doses

    Article • Clinical Pharmacology & Therapeutics, April 2012, Springer Science + Business Media

    Dr Mikko Niemi

  49. Fluconazole but not the CYP3A4 inhibitor, itraconazole, increases zafirlukast plasma concentrations

    Article • European Journal of Clinical Pharmacology, November 2011, Springer Science + Business Media

    Dr Mikko Niemi

  50. Gender, but not CYP7A1 or SLCO1B1 Polymorphism, Affects the Fasting Plasma Concentrations of Bile Acids in Human Beings

    Article • Basic & Clinical Pharmacology & Toxicology, October 2011, Wiley

    Dr Mikko Niemi

  51. Transfer of repaglinide in the dually perfused human placenta and the role of organic anion transporting polypeptides (OATPs)

    Article • European Journal of Pharmaceutical Sciences, October 2011, Elsevier

    Dr Mikko Niemi

  52. Dose-Dependent Interaction between Gemfibrozil and Repaglinide in Humans: Strong Inhibition of CYP2C8 with Subtherapeutic Gemfibrozil Doses

    Article • Drug Metabolism and Disposition, July 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mikko Niemi

  53. No significant effect of the SLCO1B1 polymorphism on the pharmacokinetics of ursodeoxycholic acid

    Article • European Journal of Clinical Pharmacology, June 2011, Springer Science + Business Media

    Dr Mikko Niemi

  54. Orange and apple juice greatly reduce the plasma concentrations of the OATP2B1 substrate aliskiren

    Article • British Journal of Clinical Pharmacology, April 2011, Wiley

    Dr Mikko Niemi

  55. Mechanism-Based Inactivation of CYP2C8 by Gemfibrozil Occurs Rapidly in Humans

    Article • Clinical Pharmacology & Therapeutics, March 2011, Springer Science + Business Media

    Dr Mikko Niemi

  56. Itraconazole, a P-Glycoprotein and CYP3A4 Inhibitor, Markedly Raises the Plasma Concentrations and Enhances the Renin-Inhibiting Effect of Aliskiren

    Article • The Journal of Clinical Pharmacology, March 2011, Wiley

    Dr Mikko Niemi

  57. Pharmacokinetics of Intravenous Paracetamol in Elderly Patients

    Article • Clinical Pharmacokinetics, February 2011, Springer Science + Business Media

    Dr Mikko Niemi

  58. Organic Anion Transporting Polypeptide 1B1: a Genetically Polymorphic Transporter of Major Importance for Hepatic Drug Uptake

    Article • Pharmacological Reviews, January 2011, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mikko Niemi

  59. Practical recommendations for pharmacogenomics-based prescription: 2010 ESF–UB Conference on Pharmacogenetics and Pharmacogenomics

    Article • Pharmacogenomics, January 2011, Future Medicine

    Dr Anke H Maitland-van der Zee, Dr Mikko Niemi

  60. Frequencies of Single-Nucleotide Polymorphisms of SLCO1A2, SLCO1B3 and SLCO2B1 Genes in a Finnish Population

    Article • Basic & Clinical Pharmacology & Toxicology, December 2010, Wiley

    Dr Mikko Niemi

  61. SLCO1B1 Polymorphism and Oral Antidiabetic Drugs

    Article • Basic & Clinical Pharmacology & Toxicology, September 2010, Wiley

    Dr Mikko Niemi

  62. Grapefruit Juice Greatly Reduces the Plasma Concentrations of the OATP2B1 and CYP3A4 Substrate Aliskiren

    Article • Clinical Pharmacology & Therapeutics, July 2010, Springer Science + Business Media

    Dr Mikko Niemi

  63. Gemfibrozil Markedly Increases the Plasma Concentrations of Montelukast: A Previously Unrecognized Role for CYP2C8 in the Metabolism of Montelukast

    Article • Clinical Pharmacology & Therapeutics, June 2010, Springer Science + Business Media

    Dr Mikko Niemi

  64. Effect of ABCB1 haplotypes on the pharmacokinetics and renin-inhibiting effect of aliskiren

    Article • European Journal of Clinical Pharmacology, May 2010, Springer Science + Business Media

    Dr Mikko Niemi

  65. Long-Term Changes in Cyclosporine Pharmacokinetics After Renal Transplantation in Children: Evidence for Saturable Presystemic Metabolism and Effect ofNR1I2Polymorphism

    Article • The Journal of Clinical Pharmacology, May 2010, Wiley

    Dr Mikko Niemi

  66. Membrane transporters in drug development

    Article • Nature Reviews Drug Discovery, March 2010, Springer Science + Business Media

    Dr Mikko Niemi

  67. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren

    Article • European Journal of Clinical Pharmacology, February 2010, Springer Science + Business Media

    Dr Mikko Niemi

  68. High performance liquid chromatography–tandem mass spectrometry for the determination of bile acid concentrations in human plasma

    Article • Journal of Chromatography B, January 2010, Elsevier

    Dr Mikko Niemi

  69. Transporter Pharmacogenetics and Statin Toxicity

    Article • Clinical Pharmacology & Therapeutics, November 2009, Springer Science + Business Media

    Dr Mikko Niemi

  70. Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

    Article • Pharmacogenomics, October 2009, Future Medicine

    Dr Mikko Niemi

  71. UDP-Glucuronosyltransferase (UGT) Polymorphisms Affect Atorvastatin Lactonization In Vitro and In Vivo

    Article • Clinical Pharmacology & Therapeutics, September 2009, Springer Science + Business Media

    Dr Mikko Niemi

  72. Impact of OATP transporters on pharmacokinetics

    Article • British Journal of Pharmacology, September 2009, Wiley

    Dr Mikko Niemi

  73. CYP2C8 Activity Recovers within 96 Hours after Gemfibrozil Dosing: Estimation of CYP2C8 Half-Life Using Repaglinide as an in Vivo Probe

    Article • Drug Metabolism and Disposition, September 2009, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mikko Niemi

  74. No significant effect ofABCB1haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin

    Article • British Journal of Clinical Pharmacology, August 2009, Wiley

    Dr Mikko Niemi

  75. Effect of SLCO1B1 polymorphism on the plasma concentrations of bile acids and bile acid synthesis marker in humans

    Article • Pharmacogenetics and Genomics, June 2009, Wolters Kluwer Health

    Dr Mikko Niemi

  76. ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

    Article • Clinical Pharmacology & Therapeutics, May 2009, Springer Science + Business Media

    Dr Mikko Niemi

  77. The effect ofSLCO1B1polymorphism on repaglinide pharmacokinetics persists over a wide dose range

    Article • British Journal of Clinical Pharmacology, December 2008, Wiley

    Dr Mikko Niemi

  78. Effects of the SLCO1B1*1B haplotype on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide

    Article • Pharmacogenetics and Genomics, November 2008, Wolters Kluwer Health

    Dr Mikko Niemi

  79. Polymorphism of the hepatic influx transporter organic anion transporting polypeptide 1B1 is associated with increased cholesterol synthesis rate

    Article • Pharmacogenetics and Genomics, October 2008, Wolters Kluwer Health

    Dr Mikko Niemi

  80. Effects of Gemfibrozil and Atorvastatin on the Pharmacokinetics of Repaglinide in Relation to SLCO1B1 Polymorphism

    Article • Clinical Pharmacology & Therapeutics, April 2008, Springer Science + Business Media

    Dr Mikko Niemi

  81. ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin

    Article • Clinical Pharmacology & Therapeutics, March 2008, Springer Science + Business Media

    Dr Mikko Niemi

  82. The Effect of Gemfibrozil on Repaglinide Pharmacokinetics Persists for at Least 12 h After the Dose: Evidence for Mechanism-based Inhibition of CYP2C8 In Vivo

    Article • Clinical Pharmacology & Therapeutics, March 2008, Springer Science + Business Media

    Dr Mikko Niemi

  83. Different Effects ofSLCO1B1Polymorphism on the Pharmacokinetics and Pharmacodynamics of Repaglinide and Nateglinide

    Article • The Journal of Clinical Pharmacology, March 2008, Wiley

    Dr Mikko Niemi

  84. Pharmacogenetics of cyclosporine in children suggests an age-dependent influence of ABCB1 polymorphisms

    Article • Pharmacogenetics and Genomics, February 2008, Wolters Kluwer Health

    Dr Mikko Niemi

  85. Global analysis of genetic variation in SLCO1B1

    Article • Pharmacogenomics, January 2008, Future Medicine

    Dr Mikko Niemi

  86. No significant effect ofSLCO1B1polymorphism on the pharmacokinetics of rosiglitazone and pioglitazone

    Article • British Journal of Clinical Pharmacology, January 2008, Wiley

    Dr Mikko Niemi

  87. Pharmacokinetic Comparison of the Potential Over-the-Counter Statins Simvastatin, Lovastatin, Fluvastatin and Pravastatin

    Article • Clinical Pharmacokinetics, January 2008, Springer Science + Business Media

    Dr Mikko Niemi

  88. Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism

    Article • The Pharmacogenomics Journal, October 2007, Springer Science + Business Media

    Dr Mikko Niemi

  89. Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone

    Article • Drug Metabolism and Disposition, October 2007, American Society for Pharmacology & Experimental Therapeutics (ASPET)

    Dr Mikko Niemi

  90. Role of OATP transporters in the disposition of drugs

    Article • Pharmacogenomics, July 2007, Future Medicine

    Dr Mikko Niemi

  91. Effects of clarithromycin and grapefruit juice on the pharmacokinetics of glibenclamide

    Article • British Journal of Clinical Pharmacology, June 2007, Wiley

    Dr Mikko Niemi

  92. Different Effects of SLCO1B1 Polymorphism on the Pharmacokinetics of Atorvastatin and Rosuvastatin

    Article • Clinical Pharmacology & Therapeutics, May 2007, Springer Science + Business Media

    Dr Mikko Niemi

  93. Stereoselective interaction between the CYP2C8 inhibitor gemfibrozil and racemic ibuprofen

    Article • European Journal of Clinical Pharmacology, February 2007, Springer Science + Business Media

    Dr Mikko Niemi

  94. Influence of Drug Transporter Polymorphisms on Pravastatin Pharmacokinetics in Humans

    Article • Pharmaceutical Research, December 2006, Springer Science + Business Media

    Dr Mikko Niemi

  95. Drug interactions with lipid-lowering drugs: Mechanisms and clinical relevance

    Article • Clinical Pharmacology & Therapeutics, December 2006, Springer Science + Business Media

    Dr Mikko Niemi

  96. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid

    Article • Pharmacogenetics and Genomics, December 2006, Wolters Kluwer Health

    Dr Mikko Niemi

  97. Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics

    Article • Pharmacogenetics and Genomics, November 2006, Wolters Kluwer Health

    Dr Mikko Niemi

  98. SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin

    Article • Clinical Pharmacology & Therapeutics, October 2006, Springer Science + Business Media

    Dr Mikko Niemi

  99. Cyclosporine A Increases Plasma Concentrations and Effects of Repaglinide

    Article • American Journal of Transplantation, September 2006, Wiley

    Dr Mikko Niemi

  100. Effect of SLCO1B1 polymorphism on induction of CYP3A4 by rifampicin

    Article • Pharmacogenetics and Genomics, August 2006, Wolters Kluwer Health

    Dr Mikko Niemi

  101. Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes

    Article • British Journal of Clinical Pharmacology, June 2006, Wiley

    Dr Mikko Niemi

  102. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone

    Article • European Journal of Clinical Pharmacology, May 2006, Springer Science + Business Media

    Dr Mikko Niemi

  103. Impact of the SLCO1B1 polymorphism on the pharmacokinetics and lipid-lowering efficacy of multiple-dose pravastatin

    Article • Clinical Pharmacology & Therapeutics, May 2006, Springer Science + Business Media

    Dr Mikko Niemi

  104. Itraconazole, gemfibrozil and their combination markedly raise the plasma concentrations of loperamide

    Article • European Journal of Clinical Pharmacology, April 2006, Springer Science + Business Media

    Dr Mikko Niemi

  105. Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population

    Article • European Journal of Clinical Pharmacology, April 2006, Springer Science + Business Media

    Dr Mikko Niemi

  106. Telithromycin, but not montelukast, increases the plasma concentrations and effects of the cytochrome P450 3A4 and 2C8 substrate repaglinide

    Article • Clinical Pharmacology & Therapeutics, March 2006, Springer Science + Business Media

    Dr Mikko Niemi

  107. Muscle Symptoms Associated with Statins: A Series of Twenty Patients

    Article • Basic & Clinical Pharmacology & Toxicology, January 2006, Wiley

    Dr Mikko Niemi

  108. Cyclosporine markedly raises the plasma concentrations of repaglinide

    Article • Clinical Pharmacology & Therapeutics, October 2005, Springer Science + Business Media

    Dr Mikko Niemi

  109. Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide

    Article • British Journal of Clinical Pharmacology, August 2005, Wiley

    Dr Mikko Niemi

  110. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics

    Article • Clinical Pharmacology & Therapeutics, June 2005, Springer Science + Business Media

    Dr Mikko Niemi

  111. Acute effects of pravastatin on cholesterol synthesis are associated with SLCO1B1 (encoding OATP1B1) haplotype *17

    Article • Pharmacogenetics and Genomics, May 2005, Wolters Kluwer Health

    Dr Mikko Niemi

  112. Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1)

    Article • British Journal of Clinical Pharmacology, May 2005, Wiley

    Dr Mikko Niemi

  113. CYP3A5 Genotype is Associated with Diagnosis of Hypertension in Elderly Patients

    Article • American Journal of PharmacoGenomics, January 2005, Springer Science + Business Media

    Dr Mikko Niemi

  114. Functional interaction of intestinal CYP3A4 and P-glycoprotein

    Article • Fundamental and Clinical Pharmacology, December 2004, Wiley

    Dr Mikko Niemi

  115. Effects of trimethoprim and rifampin on the pharmacokinetics of the cytochrome P450 2C8 substrate rosiglitazone

    Article • Clinical Pharmacology & Therapeutics, September 2004, Springer Science + Business Media

    Dr Mikko Niemi

  116. Lipid-lowering response to statins is affected by CYP3A5 polymorphism

    Article • Pharmacogenetics, August 2004, Wolters Kluwer Health

    Dr Mikko Niemi

  117. Characterisation of cerivastatin as a P-glycoprotein substrate: studies in P-glycoprotein-expressing cell monolayers and mdr1a/b knock-out mice

    Article • Naunyn-Schmiedeberg s Archives of Pharmacology, July 2004, Springer Science + Business Media

    Dr Mikko Niemi

  118. High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

    Article • Pharmacogenetics, July 2004, Wolters Kluwer Health

    Dr Mikko Niemi

  119. The CYP2C8 inhibitor trimethoprim increases the plasma concentrations of repaglinide in healthy subjects

    Article • British Journal of Clinical Pharmacology, January 2004, Wiley

    Dr Mikko Niemi

  120. Rifampicin reduces plasma concentrations of celiprolol

    Article • European Journal of Clinical Pharmacology, January 2004, Springer Science + Business Media

    Dr Mikko Niemi

  121. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone

    Article • Diabetologia, October 2003, Springer Science + Business Media

    Dr Mikko Niemi

  122. Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

    Article • Clinical Pharmacology & Therapeutics, October 2003, Springer Science + Business Media

    Dr Mikko Niemi

  123. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of nateglinide in healthy subjects

    Article • British Journal of Clinical Pharmacology, August 2003, Wiley

    Dr Mikko Niemi

  124. Effect of fluconazole on the pharmacokinetics and pharmacodynamics of nateglinide

    Article • Clinical Pharmacology & Therapeutics, July 2003, Springer Science + Business Media

    Dr Mikko Niemi

  125. Pharmacokinetic Interactions with Rifampicin

    Article • Clinical Pharmacokinetics, January 2003, Springer Science + Business Media

    Dr Mikko Niemi

  126. Plasma concentrations of inhaled budesonide and its effects on plasma cortisol are increased by the cytochrome P4503A4 inhibitor itraconazole

    Article • Clinical Pharmacology & Therapeutics, October 2002, Springer Science + Business Media

    Dr Mikko Niemi

  127. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes*

    Article • Clinical Pharmacology & Therapeutics, September 2002, Springer Science + Business Media

    Dr Mikko Niemi

  128. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride

    Article • Clinical Pharmacology & Therapeutics, November 2001, Springer Science + Business Media

    Dr Mikko Niemi

  129. The cytochrome P4503A4 inhibitor clarithromycin increases the plasma concentrations and effects of repaglinide

    Article • Clinical Pharmacology & Therapeutics, July 2001, Springer Science + Business Media

    Dr Mikko Niemi

  130. Effects of rifampin on the pharmacokinetics and pharmacodynamics of glyburide and glipizide

    Article • Clinical Pharmacology & Therapeutics, June 2001, Springer Science + Business Media

    Dr Mikko Niemi

  131. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride

    Article • Clinical Pharmacology & Therapeutics, April 2001, Springer Science + Business Media

    Dr Mikko Niemi

  132. Effect of rifampicin on the pharmacokinetics and pharmacodynamics of glimepiride

    Article • British Journal of Clinical Pharmacology, December 2000, Wiley

    Dr Mikko Niemi

  133. Rifampin decreases the plasma concentrations and effects of repaglinide

    Article • Clinical Pharmacology & Therapeutics, November 2000, Springer Science + Business Media

    Dr Mikko Niemi

  134. Effect of fluconazole on plasma fluvastatin and pravastatin concentrations

    Article • European Journal of Clinical Pharmacology, June 2000, Springer Science + Business Media

    Dr Mikko Niemi